An Angel Capital Model for the Life Sciences
Since 2005, LSA has invested nearly $50 million in over 40 companies which have received an additional $1 billion in follow-on funding from VCs and strategics.
We connect entrepreneurs with domain experts, industry veterans, premier law firms, venture capital resources, and strategic partners throughout the industry. LSA members include several leading venture capital partnerships and other angel organizations nationwide.
We syndicate deals and participate in follow-on rounds, to ensure that our companies can continue hit critical milestones and grow. Direct investments are typically $250k-$750k, with syndicated financings ranging $1.5M-$6M.
We draw on our members’ deep domain expertise in medical technology and operations to provide companies with unique, specific, industry-relevant insights. We take board seats and work side by side with entrepreneurs to drive companies toward their goals.
Life Science Angels, Inc. was founded in 2004 by senior life science executives and experienced angel investors as a vehicle to bring angel capital to worthy early stage biotech and medical device companies.
Formally launched in January 2005 with backing from 15 industry sponsors, LSA follows a rigorous due diligence process before presenting investment opportunities to its membership. LSA also works with select angel groups, venture capitalists and outside investors to syndicate opportunities requiring larger investments.
Life Science Angels is a not-for-profit corporation that takes no carry or management fees on any investment. We do not charge companies any fees to apply or present and prohibit members from seeking any form of compensation related to LSA consideration.
Learn more about our partners
Our Portfolio Companies
Combining biometrics, neurometrics and psychometrics to deliver unprecedented understanding of consumer behavior. Acquired by Nielsen in 2015
Improving maternal and fetal health through the development of a highly accurate, serum-based diagnostic test for preeclampsia. Acquired by Progenity in 2015
Apply for Funding Now!